Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Changes to the guidance document Temporary authorisation of human medicinal products HMV4

https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/authorisations/information/anpassung-wl-befristete-zulassung-ham.html

Philippe Calandra 21 January 2022 All news
  • ← Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 – 13 January 2022
  • Clinical trials for medicines: apply for authorisation in the UK →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Austria: FAQ Pharmacovigilance – 22-Nov-2022
  • Benfluorex: assessment of the follow-up of cases of pulmonary arterial hypertension
  • EU : List of centrally authorised products requiring a notification of a change for update of annexes
Copyright © 2018 - Pharmya - Legal terms - Quality Policy